falsefalse

Optimizing Biomarker Testing in Your Practice: Leveraging In-House Testing Strategies - Episode 4

Centralized vs Decentralized Biomarker Testing: Workflow, Control, and Collaboration Insights

,

Panelists discuss how centralized biomarker testing outsources analysis to specialized laboratories while decentralized testing occurs in-house. In-house testing offers tighter workflow control and closer pathology collaboration but requires more resources, whereas send-out testing leverages external expertise.

Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
  • Chapters
  • descriptions off, selected
  • captions off, selected
    EP. 1: Key Considerations When Ordering Biomarker Testing
    EP. 2: The Importance of Broad Biomarker Testing: Uncovering Actionable Targets Across Tumor Types
    EP. 3: When to Choose Narrow Panel Testing Over Comprehensive Testing in Biomarker Analysis
    Now Viewing
    EP. 4: Centralized vs Decentralized Biomarker Testing: Workflow, Control, and Collaboration Insights
    EP. 5: In-House Comprehensive Genomic Profiling: Expert Insight Into Balancing Benefits and Challenges
    EP. 6: Implementing In-House Biomarker Testing: Rationale and Key Considerations
    EP. 7: Optimizing In-House Testing: Enhancing Efficiency for Timely Results and Treatment Decisions
    EP. 8: Enhancing Multidisciplinary Coordination and Treatment Planning Through In-House Testing
    EP. 9: Impact of In-House Testing on Improved Cancer Care: Timely Decisions and Enhanced Treatment Accuracy
    EP. 10: Decentralization of Biomarker Testing: Expanding Access to Targeted Therapies and Clinical Trials in Underserved Populations
    EP. 11: Mitigating Socioeconomic Disparities Through Decentralized Testing: Overcoming Barriers to Access and Equity
    EP. 12: Key Takeaways and Future Perspectives for In-House Biomarker Testing

    Video series above is prompted by the following:

    • Briefly define centralized (send-out) vs decentralized (in-house testing) biomarker testing.
    • Briefly discuss differences in workflow, control over testing, and collaboration with pathology teams, etc

    Related Content:

    Optimizing Biomarker Testing in Your Practice: Leveraging In-House Testing Strategies ClinicalVideo SeriesBreast CancerInsights
    Denosumab Biosimilars Earn Positive CHMP Opinion for Osteoporosis and Cancer-Related Bone Disease
    Guiding Patients Through CAR T: Key Discussion Points
    CAR-T in Third-Line-Plus LBCL: Treatment Sequencing and Patient Selection
    x